Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Address: 72 Steel Road Spartan , Kempton Park ,South Africa
Tel: +27 11975 0654
Sandoz, the generic pharmaceuticals division of the Novartis Group, is a global leader in the rapidly growing generics industry. With quality going back to its roots in the 19th century, Sandoz has a strong global presence covering 90% of the world’s population. We are committed to providing healthcare products and services of a consistently high standard, worldwide. We believe that consistent and reliable quality is what sets us apart from our competition, by offering customers the safety and efficacy associated with reference medicines, at lower cost.
At Sandoz we make far more than just traditional off-patent medicines. We develop and manufacture a wide range of difficult-to-make medicines, ranging from complex delivery systems for standard generics through to modern biopharmaceutical medicines (biosimilars).
Adhering to one, uniform standard, Sandoz South Africa supplies a comprehensive range of medicines for just about every therapeutic area, from Cardiovascular, Anti-Infectives, CNS, Analgesics, and the challenging field of TB.
Our core business lies in the development, production and distribution of high-quality, affordable generic medicines. We offer approximately 1 000 generic compounds worldwide and are a leading provider of differentiated, value-added products, including state-of-the-art biosimilars, injectables, inhalers and transdermal patches.
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
